| 1 |
Dhillon S. Trastuzumab emtansine: a review of its use in patients with HER2-positive advanced breast cancer previously treated with trastuzumab-based therapy[J]. Drugs, 2014, 74(6):675-686.
|
| 2 |
Hagan CR, Lange CA. Molecular determinants of context-dependent progesterone receptor action in breast cancer[J]. BMC Med, 2014, 12:32.
|
| 3 |
幸天勇，侯令密，邓世山．泛素化调节膜联蛋白A2表达异常在乳腺癌中的作用研究[J/CD]．中华妇幼临床医学杂志：电子版，2013，9(2)：130-134.
|
| 4 |
侯令密，幸天勇，邓世山．Annexin A2与乳腺癌关系的研究进展[J/CD]．中华临床医师杂志：电子版，2011，5(14)：4206-4208.
|
| 5 |
幸天勇，侯令密，汪建国，等．膜联蛋白A2在人乳腺癌组织中的差异表达及意义[J/CD]．中华临床医师杂志：电子版，2011，5(18)：5310-5313.
|
| 6 |
Mirnezami R, Nicholson J, Darzi A. Preparing for precision medicine[J]. N Engl J Med, 2012, 366(6):489-491.
|
| 7 |
Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med, 2009, 361(10):947-957.
|
| 8 |
Knutson TP, Lange CA. Tracking progesterone receptor-mediated actions in breast cancer[J]. Pharmacol Ther, 2014, 142(1):114-125.
|
| 9 |
Sachdev D. Targeting the type Ⅰ insulin-like growth factor system for breast cancer therapy[J]. Curr Drug Targets, 2010, 11(9):1121-1132.
|
| 10 |
Shimizu A, Nakayama H, Wang P, et al. Netrin-1 promotes glioblastoma cell invasiveness and angiogenesis by multiple pathways including activation of RhoA, cathepsin B, and cAMP-response element-binding protein[J]. J Biol Chem, 2013, 288(4):2210-2222.
|
| 11 |
Zhang Q, Zhao Z, Ma Y, et al. Combined expression of S100A4 and Annexin A2 predicts disease progression and overall survival in patients with urothelial carcinoma[J]. Urol Oncol, 2014, 32(6):798-805.
|
| 12 |
Bydoun M, Waisman DM. On the contribution of S100A10 and annexin A2 to plasminogen activation and oncogenesis: an enduring ambiguity[J]. Future Oncol, 2014, 10(15):2469-2479.
|
| 13 |
Deng S, Zhou H, Xiong R, et al. Over-expression of genes and proteins of ubiquitin specific peptidases (USPs) and proteasome subunits (PSs) in breast cancer tissue observed by the methods of RFDD-PCR and proteomics[J]. Breast Cancer Res Treat, 2007, 104(1):21-30.
|
| 14 |
Zhang PW, Chen L, Huang T, et al. Classifying ten types of major cancers based on reverse phase protein array profiles[J]. PLoS One, 2015, 10(3):e0123147.
|
| 15 |
Cox E, Uzoma I, Guzzo C, et al. Identification of SUMO E3 ligase-specific substrates using the HuProt human proteome microarray[J]. Methods Mol Biol, 2015, 1295:455-463.
|
| 16 |
Smith SE, Koegl M, Jentsch S. Role of the ubiquitin/proteasome system in regulated protein degradation in Saccharomyces cerevisiae[J]. Biol Chem, 1996, 377(7-8):437-446.
|
| 17 |
Murakami Y, Matsufuji S, Kameji T, et al. Ornithine decarboxylase is degraded by the 26S proteasome without ubiquitination[J]. Nature, 1992, 360(6404):597-599.
|
| 18 |
Bird LM. Angelman syndrome: review of clinical and molecular aspects[J]. Appl Clin Genet, 2014, 7:93-104.
|
| 19 |
Słopień A, Rajewski A. Genetic studies in autistic disorders [J]. Psychiatr Pol, 2000, 34(3):435-446.
|
| 20 |
Zheng L, Foley K, Huang L, et al. Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer[J]. PLoS One, 2011, 6(4):e19390.
|
| 21 |
Gao S, Fang L, Phan LM, et al. COP9 signalosome subunit 6 (CSN6) regulates E6AP/UBE3A in cervical cancer[J]. Oncotarget, 2015, 6(29):28026-28041.
|
| 22 |
Malecka KA, Fera D, Schultz DC, et al. Identification and characterization of small molecule human papillomavirus E6 inhibitors[J]. ACS Chem Biol, 2014, 9(7):1603-1612.
|
| 23 |
Santarosa M, Del Col L, Viel A, et al. BRCA1 modulates the expression of hnRNPA2B1 and KHSRP[J]. Cell Cycle, 2010, 9(23):4666-4673.
|